Marbury TC - Search Results

1

Reduced hepatic impairment study to evaluate pharmacokinetics and safety of zavegepant and to inform dosing recommendation for hepatic impairment.

Bhardwaj R, Donohue MK, Madonia J, Morris B, Marbury TC, Matschke KT, Croop R, Bertz R, Liu J. Bhardwaj R, et al. Among authors: marbury tc. Clin Transl Sci. 2024 Jul;17(7):e13813. doi: 10.1111/cts.13813. Clin Transl Sci. 2024. PMID: 39014555 Free PMC article. Clinical Trial.

2

Pharmacokinetics of repaglinide in subjects with renal impairment.

Marbury TC, Ruckle JL, Hatorp V, Andersen MP, Nielsen KK, Huang WC, Strange P. Marbury TC, et al. Clin Pharmacol Ther. 2000 Jan;67(1):7-15. doi: 10.1067/mcp.2000.103973. Clin Pharmacol Ther. 2000. PMID: 10668848 Clinical Trial.

3

Pharmacokinetics and safety of a single oral dose of once-daily alfuzosin, 10 mg, in male subjects with mild to severe renal impairment.

Marbury TC, Blum RA, Rauch C, Pinquier JL. Marbury TC, et al. J Clin Pharmacol. 2002 Dec;42(12):1311-7. doi: 10.1177/0091270002239360. J Clin Pharmacol. 2002. PMID: 12463725 Clinical Trial.

4

Pharmacokinetics of dalbavancin in patients with renal or hepatic impairment.

Marbury T, Dowell JA, Seltzer E, Buckwalter M. Marbury T, et al. J Clin Pharmacol. 2009 Apr;49(4):465-76. doi: 10.1177/0091270008330162. J Clin Pharmacol. 2009. PMID: 19318696 Clinical Trial.

5

Single-dose pharmacokinetic studies of abiraterone acetate in men with hepatic or renal impairment.

Marbury T, Lawitz E, Stonerock R, Gonzalez M, Jiao J, Breeding J, Haqq C, Verboven P, Stieltjes H, Yu M, Molina A, Acharya M, Chien C, Tran N. Marbury T, et al. J Clin Pharmacol. 2014 Jul;54(7):732-41. doi: 10.1002/jcph.253. Epub 2014 Jan 17. J Clin Pharmacol. 2014. PMID: 24374856 Clinical Trial.

6

The effect of hepatic impairment on the pharmacokinetics of asunaprevir, an HCV NS3 protease inhibitor.

Eley T, He B, Chang I, Colston E, Child M, Bedford W, Kandoussi H, Pasquinelli C, Marbury TC, Bertz RJ. Eley T, et al. Among authors: marbury tc. Antivir Ther. 2015;20(1):29-37. doi: 10.3851/IMP2773. Epub 2014 Apr 7. Antivir Ther. 2015. PMID: 24704773 Clinical Trial.

7

Single-dose pharmacokinetics and safety of daclatasvir in subjects with renal function impairment.

Garimella T, Wang R, Luo WL, Hwang C, Sherman D, Kandoussi H, Marbury TC, Alcorn H, Bertz R, Bifano M. Garimella T, et al. Among authors: marbury tc. Antivir Ther. 2015;20(5):535-43. doi: 10.3851/IMP2941. Epub 2015 Feb 5. Antivir Ther. 2015. PMID: 25654812 Clinical Trial.

8

Pharmacokinetics of hepatitis C virus NS5A inhibitor JNJ-56914845 (GSK2336805) in subjects with hepatic impairment.

Adkison KK, Gan J, Elko-Simms L, Gardner S, Dumont E, Jones LS, Saunders J, Marbury T, Smith W, Berg J, Galloway C, Stump PJ. Adkison KK, et al. J Clin Pharmacol. 2015 Sep;55(9):1042-50. doi: 10.1002/jcph.512. Epub 2015 May 25. J Clin Pharmacol. 2015. PMID: 25857714

9

Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis.

Wang X, Tirucherai G, Marbury TC, Wang J, Chang M, Zhang D, Song Y, Pursley J, Boyd RA, Frost C. Wang X, et al. Among authors: marbury tc. J Clin Pharmacol. 2016 May;56(5):628-36. doi: 10.1002/jcph.628. Epub 2015 Dec 22. J Clin Pharmacol. 2016. PMID: 26331581 Clinical Trial.

10

Pharmacokinetic Properties of Fostamatinib in Patients With Renal or Hepatic Impairment: Results From 2 Phase I Clinical Studies.

Martin P, Oliver S, Gillen M, Marbury T, Millson D. Martin P, et al. Clin Ther. 2015 Dec 1;37(12):2823-36. doi: 10.1016/j.clinthera.2015.09.016. Epub 2015 Oct 27. Clin Ther. 2015. PMID: 26519231 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

181 results

Search Page

Filters